Florida is currently home to 3768 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
Recruiting
This study will evaluate the comparative effectiveness of three smoking cessation therapies: mobile health (mHealth) application iCanQuit, mHealth application iCanQuit + Motiv8, and the Florida quit line.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/25/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Tobacco Use Cessation
Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine
Recruiting
The purpose of this research study is to find out how Avenova (0.01 % hypochlorous acid) works compared to Betadine (Povidone iodide) for reducing bacteria and patient discomfort in the eyes.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Bascom Palmer Eye Institute, Palm Beach Gardens, Florida
Conditions: Eye Infections, Bacterial
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Miami Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida
Conditions: Cutaneous Melanoma, Stage II
ProACT Post-Approval Study
Recruiting
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Gender:
MALE
Ages:
50 years and above
Trial Updated:
11/25/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Stress Urinary Incontinence
Substance Use Treatment and Its Role in Supporting Social Cognition
Recruiting
This study aims to assess changes in empathy levels before and after residential treatment among individuals with substance use disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2024
Locations: Recovery Unplugged, Ft Lauderdale, Florida
Conditions: Substance Use, Empathy
A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy
Recruiting
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Florida Cancer Specialists, Lake Mary, Florida
Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
Recruiting
This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/22/2024
Locations: Center for Morden Aesthetic Medicine, Jacksonville, Florida
Conditions: Skin Laxity, Wrinkle, Skin Condition
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Recruiting
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Inv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Solid Tumor
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Recruiting
The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors understand if Mosunetuzumab improves outcomes in people with EMZL and if it is safe to use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: University of Miami, Miami, Florida
Conditions: Extranodal Marginal Zone Lymphoma
A Novel Repetitive Synchronized Associative Stimulation Neuromodulation Approach for Spinal Cord Injury Patients
Recruiting
The purpose of this research is to explore the effect of magnetic stimulation to activate the brain, electrical spinal cord stimulation to activate spinal cord, and electrical muscle stimulation used to activate upper limb (arms), lower limb (legs) and trunk (stomach) muscles in people with spinal cord injury (SCI) and able-bodied subjects (without SCI).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
11/21/2024
Locations: University of Miami, Miami, Florida
Conditions: SCI - Spinal Cord Injury
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC
Recruiting
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida
Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer